Myriad Genetics Inc. (MYGN) exhibits 69.9% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 69.9% gross profitability converts into -47.0% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 69.9%YoY revenue trajectory of -1.6% paired with 0.28% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -1.6% // FCF YLD: 0.28%Altman Z-Score of 0.20 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.20 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $6.67 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend -44.4% net margins.
NET MARGIN: -44.4% // D/E: 0.33x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MYGN & activate live FRED threshold breach alerts.